A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

• Main Authors: Arturo Chang-Monteagudo (Author), Rolando Ochoa-Azze (Author), Yanet Climent-Ruiz (Author), Consuelo Macías-Abraham (Author), Laura Rodríguez-Noda (Author), Carmen Valenzuela-Silva (Author), Belinda Sánchez-Ramírez (Author), Rocmira Perez-Nicado (Author), Tays Hernández-García (Author), Ivette Orosa-Vázquez (Author), Marianniz Díaz-Hernández (Author), María de los Ángeles García-García (Author), Yanet Jerez-Barceló (Author), Yenisey Triana-Marrero (Author), Laura Ruiz-Villegas (Author), Luis Dairon Rodríguez-Prieto (Author), Rinaldo Puga-Gómez (Author), Pedro Pablo Guerra-Chaviano (Author), Yaíma Zúñiga-Rosales (Author), Beatriz Marcheco-Teruel (Author), Mireida Rodríguez-Acosta (Author), Enrique Noa-Romero (Author), Juliet Enríquez-Puertas (Author), Delia Porto-González (Author), Olivia Fernández-Medina (Author), Anet Valdés-Zayas (Author), Guang-Wu Chen (Author), Luís Herrera-Martínez (Author), Yury Valdés-Balbín (Author), Dagmar García-Rivera (Author), Vicente Verez-Bencomo (Author)
• Format: Book
• Published: Elsevier, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID-19, asymptomatic convalescents, both with PCR-pos...